NDI

NephroDI Therapeutics is a private, near-clinical biopharmaceutical company focused on concentration disorders of the kidney. Its lead program, NDI-5001, is an oral kidney-targeted small molecule AMPK activator being developed as a potential first-in-class treatment for congenital nephrogenic diabetes insipidus, a rare pediatric orphan kidney disease. The company is building its science around modulation of urine-concentrating function in the kidney and has highlighted additional relevance to drug-induced forms of nephrogenic diabetes insipidus. NephroDI has also formed a strategic development collaboration with The McQuade Center for Strategic Research and Development, part of the Otsuka group, and has raised Series A financing from Sound Bioventures. Overall, it is a focused rare-disease renal company built around a novel mechanistic approach for nephrogenic diabetes insipidus.